Lonza– tag –
-
Lonza Expands Collaboration with Major US Biopharma, Secures Commercial Production for Two Biologics Programs
Lonza Switzerland Overview Lonza has expanded its strategic collaboration with a leading US biopharmaceutical company, securing commercial production for two biologics programs with options for two more. This expansion reflects robust de... -
Lonza Expands Commercial ADC Payload-Linker Manufacturing Capacity at Visp to Support Growing Oncology Pipeline
BioPharma APAC Switzerland Overview CDMO giant Lonza has announced significant expansion plans for its commercial antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp, Switzerland, site. This strategic investme... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
Lonza’s OptiALTO™ Platform Leverages Raman Spectroscopy as PAT to Significantly Boost High-Cell-Density Culture Productivity
Lonza Switzerland Overview Lonza's OptiALTO™ platform is achieving significant increases in productivity for high-cell-density cultures by integrating Raman spectroscopy as a Process Analytical Technology (PAT). This innovative approach ... -
US Stem Cell Manufacturing Market Projected to Reach $40.40 Billion, Driven by iPSC Adoption and Automated Systems: Market Report
openPR.com USA Overview This article summarizes a market research report distributed via openPR.com, predicting substantial growth in the U.S. stem cell manufacturing market, driven by increased iPSC adoption and automated closed system ... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
U.S. Stem Cell Manufacturing Market Forecast to Reach $4.04 Billion, Driven by Innovative Technologies and Automation from Thermo Fisher, Lonza, and Sartorius
openPR.com USA Overview This article summarizes a report on the U.S. stem cell manufacturing market, projected to reach $4.04 billion, driven by innovative technologies and strategic initiatives from key players. Thermo Fisher Scientific... -
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
Lonza Emphasizes End-to-End Process Scalability for High-Titer AAV Production Using HEK293 Media
Lonza Switzerland Overview Lonza underscores the critical importance of end-to-end process scalability for high-titer AAV production utilizing HEK293 media. The article highlights the pivotal role of benchtop stirred-tank bioreactors in ... -
Strategic CDMO Partnerships Accelerate in Cell and Gene Therapy Market to Tackle Manufacturing and Cost Challenges
Contract Pharma USA Overview The burgeoning cell and gene therapy (CGT) market is increasingly relying on strategic CDMO partnerships to navigate complex manufacturing and cost challenges. Sponsors are actively seeking CDMOs with special...
